KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer

Slideset - Preliminary data show efficacy and manageable toxicity in 25 patients with PD-L1+, ER+/HER2- advanced breast cancer.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research